Janux Therapeutics, Inc. (JANX)
JANX Stock Price Chart
Explore Janux Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze JANX price movements and trends.
JANX Company Profile
Discover essential business fundamentals and corporate details for Janux Therapeutics, Inc. (JANX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Jun 2021
Employees
91.00
Website
https://www.januxrx.comCEO
David Alan Campbell
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Financial Timeline
Browse a chronological timeline of Janux Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.50, while revenue estimate is $1.10M.
Earnings released on 7 Aug 2025
EPS came in at -$0.55 falling short of the estimated -$0.48 by -14.58%.
Earnings released on 8 May 2025
EPS came in at -$0.38 surpassing the estimated -$0.43 by +11.63%.
Earnings released on 27 Feb 2025
EPS came in at -$0.36 surpassing the estimated -$0.49 by +26.53%.
Earnings released on 6 Nov 2024
EPS came in at -$0.51 falling short of the estimated -$0.37 by -37.84%, while revenue for the quarter reached $439.00K , missing expectations by -70.64%.
Earnings released on 7 Aug 2024
EPS came in at -$0.11 surpassing the estimated -$0.32 by +65.63%, while revenue for the quarter reached $8.90M , beating expectations by +513.59%.
Earnings released on 7 May 2024
EPS came in at -$0.30 surpassing the estimated -$0.35 by +14.29%, while revenue for the quarter reached $1.25M , beating expectations by +89.70%.
Earnings released on 8 Mar 2024
EPS came in at -$0.25 surpassing the estimated -$0.37 by +32.43%, while revenue for the quarter reached $2.46M , beating expectations by +232.57%.
Earnings released on 7 Nov 2023
EPS came in at -$0.25 surpassing the estimated -$0.46 by +45.65%, while revenue for the quarter reached $2.52M , beating expectations by +326.61%.
Earnings released on 8 Aug 2023
EPS came in at -$0.42 surpassing the estimated -$0.52 by +19.23%, while revenue for the quarter reached $1.06M , beating expectations by +20.80%.
Earnings released on 9 May 2023
EPS came in at -$0.42 surpassing the estimated -$0.49 by +14.29%, while revenue for the quarter reached $2.05M , beating expectations by +135.40%.
Earnings released on 10 Mar 2023
EPS came in at -$0.39 surpassing the estimated -$0.45 by +13.33%, while revenue for the quarter reached $2.85M , beating expectations by +324.63%.
Earnings released on 10 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.51 by +21.57%, while revenue for the quarter reached $1.81M , beating expectations by +129.49%.
Earnings released on 9 Aug 2022
EPS came in at -$0.41 falling short of the estimated -$0.37 by -10.81%, while revenue for the quarter reached $2.37M , beating expectations by +263.85%.
Earnings released on 10 May 2022
EPS came in at -$0.32 surpassing the estimated -$0.37 by +13.51%, while revenue for the quarter reached $1.59M , beating expectations by +96.08%.
Earnings released on 18 Mar 2022
EPS came in at -$0.33 falling short of the estimated -$0.30 by -10.00%, while revenue for the quarter reached $1.62M , beating expectations by +272.92%.
Earnings released on 9 Nov 2021
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $1.16M , beating expectations by +791.54%.
Earnings released on 10 Aug 2021
EPS came in at -$0.62 falling short of the estimated -$0.13 by -376.92%, while revenue for the quarter reached $482.00K , meeting expectations.
Earnings released on 11 Jun 2021
EPS came in at -$0.13 .
Earnings released on 31 Mar 2021
EPS came in at -$0.06 , while revenue for the quarter reached $380.00K .
Earnings released on 30 Sept 2020
EPS came in at -$0.10 .
JANX Stock Performance
Access detailed JANX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.